News Search Results
Oct 28, 2025, 10:15 ET As Part of November's Diabetes-related Eye Disease Month, Prevent Blindness Launches New Resources to Educate Public on the Effects Diabetes has on Vision
will host a special roundtable discussion about diabetes and eye health. Guests include Rajeev S. Ramchandran, MD, MBA, associate professor of ophthalmology at University of Rochester
More news about: Prevent Blindness
Oct 28, 2025, 09:00 ET Luminopia Collaborates with Crunchyroll to Continue Building Its Extensive Content Library for Pediatric Lazy Eye Patients
results were published in Ophthalmology, leading to the initial FDA approval for patients aged 4 to 7 years. Based on the robust real-world evidence collected through the PUPiL Registry,
More news about: Luminopia
Oct 28, 2025, 08:12 ET AMSURG Increases South Carolina Presence With Addition of Conway Surgery Center
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Oct 24, 2025, 08:30 ET Lilly to Acquire Adverum Biotechnologies
Adverum, regarding Adverum's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for ophthalmology and advancement of gene therapies. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
More news about: Eli Lilly and Company
Oct 23, 2025, 08:30 ET Improve Clinical Trial Delivery by Leveraging AI Forecasting Tools, Upcoming Webinar Hosted by Xtalks
the PPD Clinical Research Business of Thermo Fisher Scientific, Tim Mudric, Vice President Global Therapeutic Head, Neuroscience and Ophthalmology; and Dave Hiltbrand, Associate Director of Data Science, for the live webinar on Monday, November 10, 2025, with
More news about: Xtalks
Oct 23, 2025, 08:00 ET Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration. Ophthalmology. 2021;128(4):576-586. American Academy of Ophthalmology. Geographic Atrophy: Causes, Symptoms, Treatment. AAO.org. Published April 18, 2025.
More news about: Astellas Pharma Inc.
Oct 23, 2025, 08:00 ET Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Oct 22, 2025, 11:00 ET Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
company in the U.S. as well as Global Emerging Markets. Sun's high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Oct 22, 2025, 08:30 ET The Evolution of Precision Medicine in Age-Related Neurological Diseases, Upcoming Webinar Hosted by Xtalks
biomarkers and recent advances in biomarker science are redefining patient populations in areas such as cognitive decline, movement disorders and neuro-ophthalmology. By focusing on sub-classification and related endpoints, clinical trials can be more precise in measuring outcomes and evaluating emerging therapies,
More news about: Xtalks
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Oct 22, 2025, 07:00 ET Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa
The REMAIN study results were recently presented at several leading ophthalmology conferences, including: American Academy of Ophthalmology (AAO) 2025 Annual Meeting (Oct 18–20, 2025) – Allen C. Ho, MD, Wills Eye Hospital,
More news about: Nanoscope Therapeutics
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Oct 20, 2025, 09:00 ET Prevent Blindness Declares Fifth Annual Inflammatory Eye Disease (IED) Week as Oct. 20-26, 2025
Uveitis and Inflammatory Eye Diseases featuring Steven Yeh, MD, Professor and Stanley Truhlsen Jr. Chair of Ophthalmology, Truhlsen Eye Institute, University of Nebraska Medical Center. Dr. Yeh is also a volunteer on the Prevent Blindness Scientific Committee.
More news about: Prevent Blindness
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
or occlusive vasculitis. These findings, which indicate a cumulative treatment benefit with IZERVAY, were presented at the American Academy of Ophthalmology 2025 Annual Meeting (AAO 2025) during the Retina Subspeciality Day in Orlando, Fla.
More news about: Astellas Pharma Inc.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Oct 17, 2025, 17:58 ET Virtual Field Crosses 4 Million Eye Exams -- More Than All Other VR Platforms Combined
Booth #1261 at the American Academy of Ophthalmology (AAO) Annual Meeting, October 18–20, for a hands-on demo of the industry's leading VR diagnostic platform for visual testing.
More news about: Virtual Field
Oct 17, 2025, 09:11 ET NYU Langone Health Chair of Ophthalmology, Dr. Kathryn Colby, Honored with Castroviejo Medal at AAO 2025
Fla., Oct. 17, 2025 /PRNewswire/ -- NYU Langone Health ophthalmology faculty present their latest research at this year's annual meeting of the American Academy of Ophthalmology (AAO), where
More news about: NYU Langone Health
Oct 17, 2025, 08:00 ET DeFi Technologies to Attend the 2025 Maxim Growth Summit
companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. For more information and a complete agenda of the Maxim Growth
More news about: DeFi Technologies Inc.
Oct 17, 2025, 08:00 ET DeFi Technologies to Attend the 2025 Maxim Growth Summit
companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. For more information and a complete agenda of the Maxim Growth
More news about: DeFi Technologies Inc.
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion USA
Oct 16, 2025, 19:24 ET NORDIC GROUP B.V. COMPARTE DATOS DEL GEL CANALICULAR LACRIFILL®
sobre la oclusión lagrimal en el contexto de la cirugía de cataratas y refractiva, que se publicará en un próximo número de Expert Review of Ophthalmology. El autor principal, Vance Thompson, señala que "la enfermedad del ojo seco puede influir en la planificación preoperatoria, los resultados quirúrgicos,
More news about: Nordic Pharma
Oct 16, 2025, 16:43 ET DIE NORDIC GROUP B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. (USA) IM RAHMEN DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025 PATIENTENDATEN UND ERFAHRUNGSBERICHTE ZU LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE FÜR TROCKENE AUGEN, VERÖFFENTLICHEN
2025 /PRNewswire/ -- Nordic Pharma, Inc., eine Tochtergesellschaft der Nordic Group B.V., wird auf der Jahrestagung der American Academy of Ophthalmology vom 18. bis 20. Oktober in Orlando, Florida, LACRIFILL Canalicular Gel vorstellen, eine neuartige Therapie für Symptome des trockenen Auges, und
More news about: Nordic Pharma
Oct 16, 2025, 16:41 ET NORDIC GROUP B.V., PAR L'INTERMÉDIAIRE DE SA FILIALE NORDIC PHARMA, INC. (U.S.), PARTAGERA DES DONNÉES PATIENTS ET UNE ÉTUDE SUR L'EXPÉRIENCE DES PATIENTS AVEC LE GEL CANALICULAIRE LACRIFILL®, UN NOUVEAU TRAITEMENT POUR LA SÉCHERESSE OCULAIRE, PENDANT LA CONFÉRENCE 2025 DE L'ACADÉMIE AMÉRICAINE D'OPHTHALMOLOGIE (AAO)
lacrymale dans le cadre de la chirurgie de la cataracte et de la chirurgie réfractive, qui paraîtra dans un prochain numéro d'Expert Review of Ophthalmology. L'auteur principal, Vance Thompson, note que « la sécheresse oculaire peut influencer la planification préopératoire, les résultats chirurgicaux,
More news about: Nordic Pharma
Oct 16, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
subsidiary of Nordic Group B.V., will be featuring LACRIFILL Canalicular Gel, a novel therapy for dry eye symptoms, at the American Academy of Ophthalmology Annual Meeting in Orlando, FL from October 18-20 and discussing recently published LACRIFILL patient data and patient experience study results with
More news about: Nordic Pharma
Oct 16, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
subsidiary of Nordic Group B.V., will be featuring LACRIFILL Canalicular Gel, a novel therapy for dry eye symptoms, at the American Academy of Ophthalmology Annual Meeting in Orlando, FL from October 18-20 and discussing recently published LACRIFILL patient data and patient experience study results with
More news about: Nordic Pharma